EarningsQ2 2026 Earnings Report
MX:XRAY Q2 2026 EPS Results
Actual EPS$9.41
Consensus EPS$6.30
Beat/MissBeat by +$3.11
One Year Ago EPS$9.41
MX:XRAY Q2 2026 Revenue Results
Actual Revenue$16.25B
Expected Revenue$16.10B
Beat/MissBeat by +$146.07M
YoY Revenue Growth-4.06%
Earnings Announcement Details
QuarterQ2 2026
Date08/06/2026
TimeAfter Close
Conference CallThursday, August 6, 2026
MX:XRAY Upcoming Earnings
DENTSPLY SIRONA's next earnings date is estimated for October 29, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:XRAY Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Neutral
The call reflected a mixed but constructive tone: management reported near-term top-line pressures across multiple segments (notably OIS and consumables distributor headwinds in EMEA) and acknowledged tariff and geopolitical uncertainties. Offsetting these challenges were stable adjusted EBITDA and EPS, a one-time $44 million tariff refund that materially improved cash flow and EPS, continued strategic investments in sales, clinical education and R&D, expansion of dealer partnerships, and strong Wellspect performance. Management maintained full-year guidance and emphasized that improvements from the return-to-growth action plan should become more visible in Q4 and into 2027. Given balanced operational progress and strategic momentum against ongoing revenue and regional demand headwinds, the overall message is cautiously optimistic but still in turnaround mode.Company Guidance
Revenue and EPS Stability (Non-GAAP)
Q2 revenue of $898 million; adjusted EPS flat year-over-year at $0.52. Adjusted EBITDA margins were approximately flat YoY despite headwinds.
Tariff Refund Boost
Received $44 million in tariff refunds that fully hit the P&L and translated into a positive ~$0.17 per share impact to Q2 EPS; refund materially improved cash flow and margins in the quarter.
Improved Operating Cash Flow and Working Capital
Operating cash flow increased to $99 million in Q2 versus $48 million in the prior-year quarter, driven by the tariff refund and better management of accounts payable and inventory.
Balance Sheet and Capital Deployment
Ended Q2 with $239 million cash and cash equivalents; net debt/EBITDA remained at 3.2x. Opportunistic share repurchase of 1.3 million shares (~$12 million) executed in the quarter.
Wellspect Outperformance
Wellspect Healthcare revenue grew 7.1% to $86 million, driven by new product launches, geographic expansion and continued adoption of recent products.
Geographic and Product Strengths
APAC showed double-digit growth in milling systems and CADCAM in the quarter; imaging equipment increased in EMEA (growth in OTHOBOOS line). DS Core digital platform gained traction with adoption by multiple European DSO groups.
Strategic Commercial Progress
Expanded dealer partnerships (Atlanta Dental, Nashville Dental, Medline Sinclair in Canada) and increased investments in sales force, clinical education and R&D as part of the 24-month return-to-growth plan.
Maintained Full-Year Guidance
Company maintained 2026 outlook: net sales of $3.5 billion to $3.6 billion and adjusted EPS of $1.40 to $1.50 (guidance excludes tariff refunds and incremental tariff impacts).
MX:XRAY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed